interferon
alpha
ifna
therapi
despit
good
efficaci
cure
hcv
infect
lead
major
side
effect
particular
induc
strong
peripher
tcell
lymphocytopenia
analyz
earli
consequ
ifna
therapi
thymic
function
peripher
tcell
homeostasi
patient
acut
chronic
phase
hcvinfect
well
hivhcv
coinfect
patient
evolut
tcell
subset
tcell
homeostasi
estim
flow
cytometri
thymic
function
measur
quantif
tcell
receptor
excis
circl
trec
estim
intrathym
precursor
tcell
prolifer
first
four
month
follow
initi
ifna
therapi
begin
first
month
therapi
profound
lymphocytopenia
observ
tcell
subset
includ
tcell
recent
thymic
emigr
rte
associ
inhibit
intrathym
precursor
tcell
prolifer
interleukin
il
plasma
concentr
rapidli
drop
lymphocytopenia
progress
neither
consequ
higher
consumpt
cytokin
due
neutral
solubl
decreas
plasma
concentr
ifna
therapi
correl
declin
hcv
viral
load
thymic
activ
rte
concentr
blood
data
demonstr
ifnabas
therapi
rapidli
impact
thymopoiesi
consequ
perturb
tcell
homeostasi
side
effect
might
detriment
continu
ifna
therapi
may
lead
increas
level
infecti
risk
particular
hivhcv
coinfect
patient
altogeth
studi
suggest
therapeut
potenti
mainten
peripher
tcell
homeostasi
ifnatr
patient
hepat
c
viru
hcv
caus
persist
infect
approxim
two
third
case
lead
chronic
liver
diseas
liver
failur
eventu
hepatocellular
carcinoma
substanti
proport
infect
individu
common
therapi
chronic
hepat
c
consist
pegyl
interferona
ifna
ribavirin
administr
result
viral
clearanc
genotyp
genotyp
treat
patient
interferon
continu
major
compon
new
direct
act
antivir
treatment
hcv
ifna
produc
larg
amount
acut
phase
mani
viral
infect
direct
activ
interferonstimul
gene
enhanc
tcell
surviv
increas
reduc
bax
activ
contribut
clonal
expans
antigenspecif
tcell
recent
data
suggest
earli
therapeut
intervent
pegyl
ifna
rescu
polyfunct
memori
tcell
express
high
level
receptor
alpha
chain
allow
higher
rate
sustain
viral
respons
howev
despit
good
efficaci
ifnabas
therapi
lead
sustain
anemia
thrombocytopenia
neutropenia
lymphocytopenia
moreov
pegyl
ifna
therapi
enhanc
risk
infect
older
hcvinfect
patient
hivinfect
individu
independ
neutropenia
mechan
action
ifna
includ
inhibit
differ
hematopoiet
growth
factor
possibl
affect
lymphoid
differenti
earli
stage
modif
cell
home
mechan
involv
ifna
therapyassoci
leukocyt
deplet
remain
poorli
understood
other
document
strong
reduct
abil
hivinfect
patient
sustain
thymic
product
direct
consequ
drop
intrathym
precursor
tcell
prolifer
similar
thymic
impact
also
seen
earli
sivinfect
rhesu
macaqu
model
capac
thymu
produc
recent
thymic
emigr
rte
larg
part
depend
thymocyt
prolifer
inde
extens
thymocyt
prolifer
occur
tcell
receptor
beta
tcrb
alpha
tcra
chain
rearrang
extent
prolifer
directli
correl
thymic
export
extent
cell
prolifer
thymu
measur
patient
estim
peripher
blood
cell
ratio
sjbtrec
ratio
frequenc
signal
joint
tcell
receptor
excis
circl
sjtrec
produc
excis
tcrd
locu
prior
tcra
chain
rearrang
dbjbtrec
tcell
receptor
excis
circl
trec
produc
tcrbd
tcrbj
rearrang
byproduct
tcr
rearrang
process
gener
circular
chromosom
dna
excis
tcr
rearrang
respect
occur
dbjbtrec
dp
sjtrec
stage
differenti
due
fact
trec
replic
mitosi
increas
prolifer
dp
lead
reduct
dbjbtrec
frequenc
rte
compar
sjtrec
frequenc
consequ
increas
sjbtrec
ratio
correl
initi
plasma
ifna
level
speed
thymic
dysfunct
observ
hiv
primari
infect
suggest
ifna
produc
part
innat
immun
respons
infect
particip
impair
thymopoiesi
howev
direct
evid
relationship
ifna
product
thymic
dysfunct
provid
studi
contrast
arizcorreta
colleagu
show
ifna
ribavirin
therapi
induc
substanti
reduct
circul
sjtrec
hivhcv
coinfect
patient
accompani
sustain
tcell
defect
suggest
thymic
dysfunct
similarli
sivinfect
rhesu
macaqu
model
show
ifna
therapi
induc
strong
decreas
circul
rte
number
defin
either
sjtrec
frequenc
number
hi
express
tcell
interestingli
anim
recombin
interleukin
il
therapi
abrog
deleteri
effect
ifna
therapi
key
cytokin
implic
variou
level
thymocyt
differenti
allow
cell
surviv
rearrang
process
implic
extens
thymocyt
prolifer
particular
intermedi
singl
posit
isp
earli
dp
cell
prolifer
particip
develop
tcell
divers
regul
ifna
cyclindepend
kinas
inhibitor
neg
regul
allow
isp
earli
dp
thymocyt
prolifer
moreov
ifna
also
inhibit
depend
prolifer
modul
common
c
chain
particip
togeth
receptor
investig
earli
impact
ifna
therapi
thymic
function
tcell
homeostasi
hcvinfect
hivhcv
coinfect
patient
start
ifna
therapi
first
evalu
evolut
tcell
subset
three
group
hcv
infect
individu
acut
hcv
infect
n
defin
month
post
estim
date
infect
chronic
hcv
infect
n
defin
month
post
estim
date
infect
hivhcv
coinfect
individu
n
group
patient
enrol
begin
ifna
therapi
follow
total
month
group
patient
tcell
count
significantli
differ
healthi
individu
figur
earli
one
month
follow
treatment
initi
tcell
count
significantli
reduc
chronic
hcvinfect
patient
decreas
respect
p
figur
top
central
panel
similar
trend
also
observ
compart
decreas
figur
bottom
central
panel
compar
effect
also
observ
coinfect
patient
mean
cell
count
declin
tcell
compart
tcell
subset
p
figur
right
panel
contrast
tcell
count
bare
affect
acutelyhcv
infect
patient
ifna
therapi
figur
left
panel
similarli
central
memori
tcell
tcm
demonstr
decreas
hcv
hivhcv
patient
respect
tcm
effector
memori
tem
tcell
count
declin
group
tem
figur
within
tcell
rte
identifi
higher
express
platelet
endotheli
cell
adhes
number
rte
similar
hcvinfect
patient
studi
entri
healthi
individu
data
demonstr
earli
one
month
follow
treatment
initi
ifna
induc
stronger
alter
tcell
subset
specif
rte
compart
tcell
subset
suggest
specif
effect
thymopoiesi
thu
analyz
evolut
intrathym
precursor
tcell
prolifer
peripher
tcell
cycl
plasma
concentr
receptor
alpha
chain
express
differ
factor
affect
naiv
tcell
homeostasi
despit
differ
group
studi
entri
rte
cycl
rate
estim
measur
express
chang
significantli
followup
period
figur
data
demonstr
observ
chang
sjtrec
frequenc
consequ
variat
rte
prolifer
ifna
therapi
probabl
due
reduc
thymic
product
thu
estim
thymic
output
quantif
sjbtrec
ratio
group
patient
figur
sj
btrec
ratio
estim
extent
thymocyt
prolifer
tcrb
rearrang
excis
tcell
receptor
delta
tcrd
locu
paramet
directli
reflect
extent
thymic
product
contrarili
sjtrec
valu
independ
peripher
rte
prolifer
surviv
capac
sjbtrec
ratio
alreadi
low
hivinfect
patient
compar
healthi
control
donor
figur
bottom
left
panel
evolv
ifna
therapi
coinfect
patient
figur
bottom
right
panel
contrast
acut
hcvinfect
patient
demonstr
higher
normal
sjbtrec
ratio
baselin
compar
age
match
healthi
control
show
signific
reduct
sjbtrec
ratio
p
p
figur
top
panel
final
similar
declin
sjbtrec
ratio
observ
ifna
therapi
chronic
hcvinfect
patient
figur
central
panel
precursor
tcell
prolifer
thymu
least
part
depend
upon
thu
quantifi
plasma
concentr
group
patient
studi
entri
hcvand
hiv
hcvinfect
patient
present
elev
plasma
median
pgml
rang
acut
hcvinfect
patient
pgml
chronic
hcvinfect
patient
pgml
coinfect
subject
compar
observ
healthi
control
individu
patient
group
figur
surprisingli
lymphocytopenia
establish
plasma
concentr
significantli
decreas
group
hcvinfect
patient
decreas
acut
infect
decreas
chronic
infect
figur
left
central
panel
contrast
plasma
level
significantli
evolv
coinfect
individu
first
month
ifna
therapi
figur
right
panel
patient
highest
plasma
level
show
reduct
concentr
cytokin
decreas
plasma
concentr
could
consequ
reduc
product
increas
consumpt
tcell
sequestr
solubl
receptor
hcvinfect
hivhcv
coinfect
patient
neither
consid
variat
paramet
use
evalu
thymic
function
sought
evalu
impact
chang
plasma
level
de
novo
product
thymu
number
sjtrec
circul
rte
major
patient
plasma
level
sjbtrec
ratio
sjtrecml
blood
rte
concentr
fluctuat
parallel
figur
variat
plasma
concentr
first
month
therapi
correl
variat
tcell
count
tcell
count
rte
tcell
count
drte
tcell
count
hcv
r
p
r
p
figur
left
panel
lesser
extent
hivhcv
coinfect
patient
r
p
r
p
figur
right
panel
moreov
hcvinfect
patient
also
correl
variat
intrathym
precursor
tcell
prolifer
dsjbtrec
ratio
r
p
figur
variat
plasma
level
also
correl
chang
proport
r
p
figur
left
panel
number
r
p
figur
left
panel
cycl
rte
acut
chronic
hcv
infect
patient
count
coinfect
patient
r
p
figur
right
panel
overal
concentr
associ
reduc
thymopoiesi
rte
prolifer
lower
consequ
lead
limit
circul
rte
tcell
count
data
strongli
suggest
chang
plasma
level
ifna
therapi
directli
impact
homeostasi
rte
herein
demonstr
ifnabas
therapi
lead
major
lymphocytopenia
tcell
compart
particular
rte
subset
sever
mechan
could
implic
establish
lymphocytopenia
among
enhanc
apoptosi
cell
sequestr
lymphoid
nonlymphoid
organ
regul
peripher
tcell
homeostasi
studi
major
chang
cell
surviv
express
tcell
activ
express
observ
followup
period
data
shown
moreov
observ
signific
modif
express
tcell
subset
first
month
therapi
data
shown
figur
final
ifnainduc
tcell
home
although
rapid
massiv
transient
process
suggest
mechan
margin
contribut
observ
long
last
lymphocytopenia
interestingli
sjtrec
quantif
sjtrecml
intrathym
precursor
tcell
prolifer
sjbtrec
ratio
affect
earli
initi
therapi
figur
sjtrec
frequenc
concentr
peripher
blood
affect
modif
paramet
impact
peripher
tcell
homeostasi
cycl
survivalapoptosi
home
sjbtrec
ratio
marker
intrathym
prolifer
histori
rte
inde
paramet
gener
cell
prolifer
occur
tcrb
chain
rearrang
excis
tcrd
locu
cell
cycl
tcra
chain
rearrang
modifi
sjbtrec
ratio
type
trec
similarli
dilut
upon
cell
prolifer
accordingli
export
peripheri
sjbtrec
ratio
matur
tcell
modifi
therefor
observ
decreas
sjtrec
concentr
figur
consequ
modif
circul
tcell
homeostasi
declin
sjbtrec
ratio
observ
first
month
ifna
therapi
figur
defin
chang
thymocyt
prolifer
thu
thymic
output
acut
infect
patient
demonstr
higher
sjbtrec
ratio
baselin
patient
chronic
phase
howev
group
younger
median
versu
median
chronic
group
data
shown
demonstr
normal
sjbtrec
ratio
age
similar
evolut
thymic
function
circul
tcell
subset
observ
group
hcvinfect
patient
irrespect
develop
stage
hcv
patholog
lack
effect
ifna
therapi
hivhcv
coinfect
patient
might
due
fact
expect
chronic
hivinfect
individu
patient
alreadi
low
thymic
function
studi
entri
impair
thymopoiesi
hcvinfect
patient
ifna
therapi
reminisc
observ
acut
phase
infect
suggest
long
term
product
ifna
part
antihiv
innat
immun
respons
may
play
role
observ
thymic
defect
correl
declin
plasma
level
ifna
therapi
thymic
dysfunct
reduc
tcell
count
particular
rte
compart
figur
confirm
hypothesi
final
recent
studi
show
ifna
treatment
lead
decreas
sjtrec
frequenc
well
reduc
tcell
rte
count
sivinfect
rhesu
macaqu
effect
accompani
decreas
plasma
level
anim
could
counteract
inject
recombin
simian
one
could
expect
effect
type
ifn
restrict
hivinfect
mani
viral
infect
induc
ifna
respons
caus
transient
lymphocytopenia
infect
host
moreov
ifnainduc
reduct
thymic
function
probabl
consequ
tcell
divers
may
contribut
higher
infecti
risk
associ
ifna
therapi
particular
observ
older
patient
multipl
sourc
circul
viral
infect
includ
lymphoid
organ
epitheli
cell
recent
liver
identifi
major
sourc
moreov
increas
plasma
level
also
observ
viral
infect
nonlymphopen
individu
unpublish
data
suggest
role
develop
immun
respons
inde
cytokin
particip
tcell
home
variou
lymphoid
nonlymphoid
tissu
stimul
local
chemokin
product
increas
plasma
level
lymphopen
individu
like
due
reduc
consumpt
yet
augment
product
counteract
lymphopenia
exclud
recent
identif
liver
produc
tissu
upon
tlr
stimul
make
tempt
specul
hcvinfect
also
tlr
activ
stimul
product
liver
inde
nonlymphopen
hcvinfect
patient
demonstr
similar
plasma
level
lymphopen
hivinfect
individu
suggest
product
untreat
hcvinfect
patient
link
circul
tcell
count
reduct
plasma
level
lymphocytopenia
establish
ifna
therapi
absenc
correl
plasma
level
express
concomit
decreas
plasma
level
hcv
viral
load
therapi
suggest
viremia
might
drive
product
initi
therapi
data
suggest
initi
ifna
therapi
activ
replic
hcv
lead
overproduct
subsequ
reduct
product
upon
initi
therapi
probabl
reflect
elimin
produc
hcvinfect
hepatocyt
sudden
reduct
plasma
level
may
lead
diminish
thymopoiesi
fact
plasma
level
reach
normal
level
hcv
becam
undetect
may
suggest
initi
declin
follow
drop
viremia
plasma
level
regul
hivinfect
patient
ifnatr
sivinfect
rhesu
macaqu
consequ
lymphocytopenia
either
reduc
consumpt
increas
product
lymphoid
organ
futur
studi
longer
followup
period
particular
end
ifna
therapi
recoveri
lymphocytopenia
requir
elucid
point
herein
demonstr
substanti
reduct
thymic
export
observ
hcvinfect
patient
first
month
ifna
therapi
effect
directli
parallel
ifnainduc
lymphocytopenia
decreas
plasma
level
initi
high
hcvinfect
patient
data
suggest
product
liver
consequ
activ
hcv
replic
reduc
patient
control
hcv
viremia
restrict
plasma
level
might
associ
antiprolif
effect
ifna
limit
tcell
product
thymu
studi
highlight
therapeut
potenti
complement
standard
ifna
base
treatment
help
hcvinfect
patient
sustain
normal
circul
tcell
count
restor
divers
peripher
tcell
repertoir
central
thymopoiet
effect
restor
breadth
intens
tcell
control
hcv
viru
might
immedi
benefici
hivhcv
coinfect
popul
offer
new
promis
avenu
chronic
hcv
context
massiv
drop
hcv
viral
load
short
term
treatment
new
antivir
compound
continu
administ
combin
ifna
sixteen
hcvinfect
patient
ten
hiv
hcv
coinfect
patient
ifna
therapi
enrol
studi
summari
virolog
immunolog
statu
patient
baselin
shown
tabl
hivhcv
coinfect
patient
one
haart
undetect
viremia
hiv
copiesml
chronic
infect
patient
initi
pegyl
ifnaribavirin
treatment
pegasi
mg
weekli
ribavirin
copegu
mg
mg
daili
follow
month
period
patient
includ
acut
phase
hcv
infect
treat
pegyl
ifna
pegasi
roch
mg
weekli
blood
sampl
taken
monthli
edta
two
millilit
total
blood
dilut
dmso
frozen
conserv
liquid
nitrogen
total
blood
sampl
subsequ
use
flow
cytometri
analys
plasma
separ
remain
eight
millilit
mononuclear
cell
purifi
ficol
hypaqu
eurobio
courtaboeuf
franc
frozen
analys
patient
hcv
monoinfect
group
follow
centr
de
recherch
du
chum
saint
luc
montreal
qc
canada
collabor
previous
describ
patient
hivhcv
group
follow
henri
mondor
creteil
franc
clinic
protocol
conform
figur
variat
plasma
level
correl
evolut
rte
product
correl
variat
plasma
level
either
variat
total
tcell
count
tcell
count
b
rte
defin
hi
tcell
drte
count
c
sjbtrec
ratio
dsjbtrec
ratio
frequenc
cell
rte
tcell
subset
rte
e
number
circul
rte
rte
count
studi
entri
month
therapi
calcul
acut
black
symbol
chronic
white
symbol
hcvinfect
patient
left
panel
hivhcv
coinfect
patient
right
panel
correl
coeffici
spearman
r
associ
probabl
p
shown
ethic
guidelin
author
institut
us
depart
health
human
servic
human
experiment
guidelin
studi
approv
ethic
committe
centr
hospitali
de
de
montreal
chum
ethic
committe
henri
mondor
franc
sampl
obtain
written
subject
inform
consent
immunophenotyp
flow
cytometri
analysi
fac
analys
perform
cryopreserv
sampl
thaw
blood
cell
incub
minut
conjug
monoclon
antibodi
mab
intracellular
label
cell
permeabil
cytofixcytoperm
kit
becton
dickinson
incub
specif
mab
accord
manufactur
instruct
sampl
wash
fix
paraformaldehyd
phosphatebuff
salin
pbspfa
acquir
use
cyan
cytofluoromet
dako
analyz
flowjo
softwar
monoclon
antibodi
use
studi
blue
pb
clone
dako
trapp
franc
chlorophyl
proteincyanin
clone
bd
lepontdeclaix
franc
pe
clone
bd
apc
clone
r
system
europ
lill
franc
bd
clone
abdserotec
germani
isothiocyan
fitc
clone
dako
clone
dako
strepatavidinpetexasr
bd
quantifi
plasma
use
quantikin
hs
kit
accord
manufactur
instruct
r
system
europ
plasma
quantif
solubl
plasma
receptor
quantif
perform
previous
describ
parallel
quantif
sjtrec
djbtrec
togeth
gene
use
housekeep
gene
perform
sampl
use
lightcyclertm
technolog
roch
diagnost
techniqu
adapt
intrathym
precursor
tcell
prolifer
evalu
calcul
sjbtrec
ratio
describ
hcv
rna
quantif
perform
use
inhous
quantit
realtim
revers
transcriptionpcr
assay
previous
describ
coba
amplicor
hcv
monitor
test
tm
version
sensit
iuml
qualit
coba
ampliprepcoba
amplicor
hcv
test
tm
version
sensit
iuml
abbott
realtim
hcv
assay
tm
sensit
iu
ml
statist
analys
spearman
rank
correl
wilcoxon
match
pair
signedrank
test
perform
use
stataic
stata
corpor
colleg
station
tx
usa
due
exploratori
natur
studi
correct
multipl
comparison
calcul
p
valu
report
herein
